Eisai (ESALY) stock price, revenue, and financials

Eisai market cap is $11.9 b, and annual revenue was ¥756.23 b in FY 2021

$11.9 B

ESALY Mkt cap, 24-Jun-2022

¥756.2 B

Eisai Revenue FY, 2021
Eisai Gross profit (FY, 2021)634.4 B
Eisai Net income (FY, 2021)45.7 B
Eisai EBITDA (FY, 2021)92.1 B
Eisai EBIT (FY, 2021)53.7 B
Eisai Cash, 31-Mar-2022309.6 B
Eisai EV-202.8 B
Get notified regarding key financial metrics and revenue changes at EisaiLearn more
Banner background

Eisai Revenue Breakdown

Embed Graph

Eisai revenue breakdown by business segment: 45.3% from PHARMACEUTICAL DIVERSIFIED, 9.4% from OTHER NONDISCLOSED and 45.3% from PHARMACEUTICAL DIVERSIFIED

Eisai revenue breakdown by geographic segment: 32.2% from Japan, 16.8% from Europe, 7.0% from Others, 30.0% from Americas and 14.1% from China

Eisai Income Statement

Annual

JPYFY, 2019FY, 2020FY, 2021

Revenue

695.6b645.9b756.2b

Cost of goods sold

(149.7b)(133.8b)(136.4b)

Gross profit

547.4b513.6b634.4b

R&D expense

(140.1b)(150.3b)(171.7b)

Operating expense total

(390.9b)(424.0b)(542.3b)

Depreciation and amortization

(33.7b)(36.3b)(38.4b)

EBITDA

156.5b89.5b92.1b

EBIT

123.2b53.1b53.7b

Interest expense

(1.1b)(1.2b)(1.7b)

Interest income

3.3b1.3b2.4b

Pre tax profit

128.1b52.6b54.5b

Income tax expense

(5.6b)(10.1b)(8.7b)

Net Income

122.5b42.5b45.7b

EPS

424.8146.9167.3

Quarterly

JPYQ1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Revenue

154.0b145.3b186.8b165.6b151.5b181.3b198.9b163.5b203.0b

Cost of goods sold

(34.6b)(34.9b)(32.6b)(29.6b)(32.4b)(31.3b)(29.8b)(32.4b)(32.7b)

Gross profit

124.2b111.0b155.3b136.7b118.9b150.2b182.5b131.3b170.7b

R&D expense

(29.4b)(38.6b)(35.0b)(30.5b)(37.0b)(40.6b)(41.8b)(38.1b)(43.4b)

Operating expense total

(90.1b)(99.3b)(102.5b)(95.9b)(107.9b)(117.4b)(117.7b)(117.6b)(145.5b)

Depreciation and amortization

(8.3b)(5.4b)(11.4b)(8.7b)(9.0b)(9.2b)(9.5b)(8.2b)(11.5b)

EBITDA

34.1b11.6b52.8b40.8b10.9b32.8b64.9b13.7b25.2b

EBIT

25.8b6.2b41.3b32.1b2.0b23.6b55.4b5.5b13.6b

Interest expense

(304.0m)(292.0m)(311.0m)(323.0m)(304.0m)(301.0m)(374.0m)(404.0m)(405.0m)

Interest income

1.4b888.0m1.1b651.0m330.0m613.0m749.0m470.0m648.0m

Pre tax profit

27.0b6.8b42.1b32.4b2.0b23.9b55.8b5.6b13.9b

Income tax expense

(4.9b)(1.5b)4.5b(7.7b)(614.0m)(4.2b)(13.5b)(1.3b)(843.0m)

Net Income

22.1b5.3b46.5b24.8b1.4b19.7b42.3b4.2b13.0b

EPS

75.618.6161.485.24.867.6147.014.049.4

Eisai Balance Sheet

Annual

JPYFY, 2017FY, 2018FY, 2019FY, 2020FY, 2022

Cash

214.0b204.7b221.7b207.0b309.6b

Accounts Receivable

142.9b137.3b170.1b147.4b208.0b

Inventories

80.9b67.9b65.7b85.1b99.0b

Current Assets

535.9b561.7b521.4b518.3b640.6b

PP&E

103.1b105.2b144.6b160.9b169.9b

Goodwill

165.0b172.2b168.7b171.8b191.8b

Total Assets

1.0t1.1t1.1t1.1t1.2t

Accounts Payable

36.4b31.3b31.0b28.3b108.1b

Short-term debt

16.4b49.0b35.0b40.0b

Current Liabilities

241.7b295.7b252.0b256.0b313.3b

Long-term debt

156.7b89.9b54.9b49.9b94.9b

Non-Current Liabilities

193.3b123.8b107.5b106.1b154.4b

Total Debt

173.1b138.9b89.9b89.9b94.9b

Total Liabilities

434.9b419.5b359.5b362.1b467.8b

Common Stock

45.0b146.7b129.5b151.6b45.0b

Additional Paid-in Capital

77.6b77.6b77.6b77.6b77.6b

Retained Earnings

415.0b438.5b505.4b508.0b506.6b

Total Equity

614.1b652.0b702.6b727.9b771.5b

Quarterly

JPYQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Cash

279.7b291.8b248.6b225.5b215.4b212.5b226.3b228.0b193.8b213.1b283.0b258.4b

Accounts Receivable

148.8b149.3b165.9b168.6b164.1b196.7b184.0b183.0b202.0b236.3b174.6b214.6b

Inventories

70.4b71.0b66.1b63.9b65.1b66.4b70.9b74.9b78.9b89.9b90.0b92.5b

Current Assets

549.6b562.9b520.1b487.9b472.4b500.1b501.2b504.5b495.6b562.5b570.7b587.1b

PP&E

97.8b93.9b94.4b138.0b135.2b139.1b144.3b143.1b143.5b159.1b159.3b162.4b

Goodwill

171.5b176.1b172.1b167.1b167.3b169.9b167.0b164.1b160.6b171.6b173.7b178.6b

Total Assets

1.1t1.1t1.0t1.0t1.0t1.1t1.0t1.0t1.0t1.1t1.1t1.2t

Accounts Payable

52.6b52.1b51.4b58.3b52.9b60.3b61.9b77.9b70.2b80.8b76.3b90.6b

Short-term debt

29.0b40.0b40.0b40.0b60.5b59.0b35.0b42.8b40.0b40.0b

Current Liabilities

249.5b267.3b274.0b255.4b273.2b275.7b231.5b203.2b191.4b277.9b280.8b305.0b

Long-term debt

163.0b124.0b89.9b89.9b54.9b54.9b55.0b89.9b89.9b49.9b49.9b49.9b

Non-Current Liabilities

197.7b159.3b127.7b138.6b103.1b106.7b105.5b140.6b139.9b104.1b103.9b103.7b

Total Debt

192.0b163.9b129.9b129.9b115.4b113.9b89.9b89.9b89.9b92.7b89.9b89.9b

Total Liabilities

447.2b426.5b401.7b394.1b376.3b382.4b337.0b343.8b331.4b382.0b384.8b408.7b

Common Stock

145.6b157.0b144.1b130.2b126.4b139.7b127.4b125.2b123.1b152.9b155.5b170.1b

Additional Paid-in Capital

77.5b77.6b77.6b77.6b77.6b77.6b77.6b77.7b77.6b77.6b77.6b77.6b

Retained Earnings

407.1b429.5b412.9b434.8b440.2b461.8b508.0b509.6b505.6b526.0b531.2b521.1b

Total Equity

619.4b653.7b624.3b632.1b633.8b669.0b703.3b702.8b697.2b747.4b755.3b758.7b

Eisai Cash Flow

Annual

JPYFY, 2017FY, 2018FY, 2019FY, 2020FY, 2022

Net Income

76.8b89.5b128.1b54.5b

Depreciation and Amortization

26.2b26.8b33.7b38.4b

Cash From Operating Activities

149.6b103.7b102.8b117.6b

Cash From Investing Activities

17.0b(7.9b)(27.6b)(28.8b)

Short-term Borrowings

11.4b(2.4b)(9.0b)

Long-term Borrowings

(50.0b)(33.3b)(48.9b)(5.4b)

Dividends Paid

(42.9b)(43.0b)(45.8b)(45.9b)

Cash From Financing Activities

(81.9b)(79.2b)(103.5b)(49.0b)

Net Change in Cash

83.8b21.4b(37.7b)60.9b

Quarterly

JPYQ1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020Q1, 2021Q2, 2021Q3, 2021

Net Income

21.3b49.7b59.5b27.0b33.8b75.8b32.4b34.4b58.4b55.8b61.3b75.2b

Depreciation and Amortization

6.9b13.7b20.1b8.3b16.5b25.1b8.7b17.7b26.8b9.5b19.3b29.2b

Cash From Operating Activities

12.3b49.9b60.5b(4.1b)8.4b29.2b10.0b18.6b22.1b(14.3b)68.4b73.2b

Cash From Investing Activities

(1.6b)(4.5b)3.0b(20.1b)(23.6b)(26.5b)(12.5b)(17.4b)(31.1b)124.0m(8.0b)(18.7b)

Short-term Borrowings

12.6b(11.4b)(11.4b)(9.0b)16.5b15.0b2.8b

Long-term Borrowings

5.0b(19.0m)(33.4b)(2.3b)(44.1b)(46.7b)(2.4b)(5.2b)(7.7b)(2.5b)(5.2b)(7.8b)

Dividends Paid

(22.9b)(22.9b)(43.0b)(22.9b)(22.9b)(45.8b)(22.9b)(22.9b)(45.9b)(22.9b)(22.9b)(45.9b)

Cash From Financing Activities

(5.4b)(34.5b)(88.1b)(34.2b)(50.5b)(77.6b)(25.4b)(28.3b)(53.6b)(22.5b)(27.9b)(53.4b)

Net Change in Cash

9.2b21.3b(21.9b)(66.4b)(76.5b)(79.4b)(27.9b)(26.2b)(60.5b)(35.7b)34.3b9.7b

Eisai Ratios

JPYFY, 2018

Eisai Operating Metrics

Jul, 2018Jul, 2019Jul, 2020

Phase I Trials Products

1514

Phase II Trials Products

1315

Phase I/II Trials Products

66

Phase III Trials Products

1114

Phase II/III Trials Products

11

Filed Trials Products

69

Trials Products Approved

98

Products in Pipeline (Oncology)

263734

Phase I Trials Products (Oncology)

1011

Phase II Trials Products (Oncology)

89

Phase I/II Trials Products (Oncology)

56

Phase III Trials Products (Oncology)

310

Filed Trials Products (Oncology)

2

Trials Products Approved (Oncology)

45

Products in Pipeline (Neurology)

15139

Phase I Trials Products (Neurology)

31

Phase II Trials Products (Neurology)

23

Phase III Trials Products (Neurology)

63

Phase II/III Trials Products (Neurology)

11

Filed Trials Products (Neurology)

39

Trials Products Approved (Neurology)

21

Products in Pipeline (Gastrointestinal)

74

Phase I Trials Products (Gastrointestinal)

1

Phase II Trials Products (Gastrointestinal)

12

Phase III Trials Products (Gastrointestinal)

23

Filed Trials Products (Gastrointestinal)

1

Trials Products Approved (Gastrointestinal)

31

Eisai Employee Rating

4.4116 votes
Culture & Values
3.2
Work/Life Balance
3.4
Senior Management
2.5
Salary & Benefits
3.6
Career Opportunities
2.7
Source